MAHLY (Medipal Holdings) ROCE %: 7.14% (As of Mar. 2026)

What is Medipal Holdings ROCE %?

Medipal Holdings MAHLY +5.92% 78 ROCE % is 7.14% as of Mar. 2026. GuruFocus rates MAHLY with a GF Score™ of 78/100 and a GF Value™ of $16.92 (Fairly Valued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medipal Holdings's annualized ROCE % for the quarter that ended in Mar. 2026 was 7.14%.

Medipal Holdings (OTCPK:MAHLY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medipal Holdings ROCE % Related Terms

Medipal Holdings ROCE % Historical Data

* Premium members only.

The historical data trend for Medipal Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medipal Holdings ROCE % Chart

Medipal Holdings Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

ROCE %

Get a 7-Day Free Trial

7.67

9.18

9.24

9.58

9.51

Medipal Holdings Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															5.35	9.32	10.25	12.54	7.14

78GF Score

Medipal Holdings Corp MAHLY

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Medipal Holdings ROCE % Calculation

Medipal Holdings's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	515.853	/	( ( (12243.482 - 6772.194)	+	(12112.234 - 6730.671) )	/ 2 )
	=	515.853	/	( (5471.288	+	5381.563)	/ 2 )
	=	515.853	/	5426.4255
	=	9.51 %

Medipal Holdings's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	384.92	/	( ( (12951.743 - 7544.175)	+	(12112.234 - 6730.671) )	/ 2 )
	=	384.92	/	( ( 5407.568	+	5381.563 )	/ 2 )
	=	384.92	/	5394.5655
	=	7.14 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 7.14% mean?

Medipal Holdings (MAHLY) has a ROCE % of 7.14% as of Mar. 2026.

Is Medipal Holdings' ROCE % too high?

Medipal Holdings' current ROCE % is 7.14%. The Medical Distribution industry median ROCE % is 9.22. Medipal Holdings' value of 7.14% is 22.6% below this industry median. Overall, Medipal Holdings has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Medipal Holdings' ROCE % compare to MCK and COR?

Medipal Holdings' ROCE % of 7.14% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 9.22. Medipal Holdings' value of 7.14% is 22.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Distribution company?

The median ROCE % among Medical Distribution companies is 9.22, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medipal Holdings's current ROCE % of 7.14% is 22.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 9.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medipal Holdings's current ROCE % is 7.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Medipal Holdings stock overvalued right now?

Based on GuruFocus' analysis, Medipal Holdings (MAHLY) is currently considered Fairly Valued. The stock's GF Value™ is $16.92, compared to a current price of $16.28 — trading 3.8% below its estimated fair value. The current ROCE % is 7.14% and 22.6% below the Medical Distribution industry median of 9.22. Medipal Holdings' overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Medipal Holdings (MAHLY), the current ROCE % is 7.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medipal Holdings (MAHLY) Overvalued in 2026?

Based on GuruFocus' analysis, Medipal Holdings stock appears to be undervalued. The current stock price of $16.28 is trading 3.8% below its estimated GF Value™ of $16.92. GuruFocus considers Medipal Holdings to be Fairly Valued.

Key valuation signals for MAHLY:

ROCE %: 7.14%
GF Value™: $16.92 vs. price of $16.28 (3.8% below fair value)
GF Score™: 78/100 with 1 warning sign
Industry Position: 22.6% below the Medical Distribution median

No single metric tells the full story. See the MAHLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medipal Holdings Business Description

Industry Healthcare Medical Distribution

Comparable Companies TSE:2784 TSE:9987 TSE:8129 TSE:7476 TSE:3151 TSE:3183 NGO:7488 SSE:3055 TSE:7634 TSE:2689 MCK COR CAH ASX:SIG HSIC SHSE:601607 HKSE:01099 XSWX:GALE SHSE:600332 SHSE:600998

Other Exchanges MEPDF:USA 7459:Japan

Address 3-1-1 Kyobashi, Chuo-ku, Tokyo, JPN, 104-8461

Website https://www.medipal.co.jp

Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.

78GF Score

Get the complete analysis for MAHLY

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.28

Price

$16.92

GF Value

View MAHLY Analysis

See ROCE % data for all stocks →